Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Between 1985 and 1989, four patients with uvea metastases of breast cancers were treated in the Dept. of Gynaecology and Obstetrics of the University of the Saar, Medical School, in Homburg/Saar. One of these patients developed binocular metastases. The patient's age at the primary diagnosis of breast cancer was 48 years (median), the others were in pre- or peri-menopausal status. Uvea metastases appeared in median five years after primary diagnosis, always in coincidence with at least one more metastasis of different localisation. All cases with uvea metastases have been treated by radiation therapy with 40 gy reference dose. In three out of five cases, complete remission of the visus restriction could be achieved. In a further case, a temporary partial remission occurred. Two relapses were observed after remission induction, one and four years after treatment respectively.
 ...
PMID:[Choroid metastases in metastatic breast cancer--a rare metastatic site]. 228 23

Benign metastasizing leiomyoma (BML) is a benign spindle cell lesion affecting women who have undergone hysterectomy for uterine leiomyomas in young adulthood, and subsequently present pulmonary metastases during the peri-menopausal period. We present 2 cases of BML in women with prior medical history of hysterectomy for multiple myomas. Both patients presented pulmonary metastases at 17 and 12 years after hysterectomy. The pulmonary nodules were totally excised in the both cases, and neither patient experienced complications or recurrences after 1 and 2 years of follow up, respectively. BML is a rare benign entity with a debated pathogenesis. We have developed different hypotheses about its pathogenesis, mechanisms of spread, histological characteristics and commonly employed treatment modalities.
 ...
PMID:Benign metastasizing leiomyoma: report of 2 cases and review of the literature. 1977 65

Background: Advanced hormone-receptor positive HER2 negative breast cancer is a common and a very heterogeneous disease. Hormone therapy is the main first line treatment of choice, given alone or in combination with other agents that have shown to improve patient outcomes, Nevertheless, treatment remains generally palliative rather than curative. Sequencing of such treatment remains challenging, especially with resurgence of variable resistance patterns. Multiple attempts have been made to overcome resistance and improve patient survival, yet resistance remains not very well understood and metastatic cancer remains a disease with dismal prognosis. Methods: In this paper, we searched pubmed database as well as local and international meetings for all studies discussing advanced and metastatic hormone-receptor-positive, her2-negative breast cancer, hormonal treatment, resistance to hormonal treatment, mechanism of resistance, and means to overcome such resistance. Conclusion: There does not exist an optimal treatment sequence for hormone-receptor-positive, her2-negative advanced breast cancer. However, after review of literature, a reasonable approach may be starting with tamoxifen, aromatase inhibitors, or fulvestrant in absence of visceral crisis, in addition to ensuring adequate ovarian function suppression in pre/peri-menopausal women. Aromatase inhibitors and fulvestrant seem to be superior. Resistance to such agents is increasing, mostly attributed to genetic and molecular changes. Multiple modalities are addressed to overcome such resistance including use of CKD4/6 inhibitors, mTOR inhibitors and PI3K inhibitors in addition to other agents under study, all with promising results. CDK4/6 inhibitors work best when used in frontline setting. Finally, treatment of breast cancer remains a growing field, and more studies are to be awaited.
 ...
PMID:Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. 3128 96